ASTRAZENECA PLC Form 6-K: Report of foreign private issuer
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2024-12-26: Form 6-K; Period of report 2024-12-26; Description DATO-DXD NSQ NSCLC APPLICATION WITHDRAWN IN EU; Document a1964r.htm.
- 2024-12-23: Form 6-K; Period of report 2024-12-23; Description TAGRISSO APPROVED IN EU BASED ON LAURA TRIAL; Document a0239r.htm.
- 2024-12-16: Form 6-K; Period of report 2024-12-16; Description DIRECTORATE CHANGE; Document a1209q.htm.
- 2024-12-05: Form 6-K; Period of report 2024-12-05; Description IMFINZI APPROVED IN US FOR LIMITED-STAGE SCLC; Document a8986o.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2024-12-26 | 6-K | 2024-12-26 | DATO-DXD NSQ NSCLC APPLICATION WITHDRAWN IN EU | a1964r.htm |
| 2024-12-23 | 6-K | 2024-12-23 | TAGRISSO APPROVED IN EU BASED ON LAURA TRIAL | a0239r.htm |
| 2024-12-16 | 6-K | 2024-12-16 | DIRECTORATE CHANGE | a1209q.htm |
| 2024-12-05 | 6-K | 2024-12-05 | IMFINZI APPROVED IN US FOR LIMITED-STAGE SCLC | a8986o.htm |
| 2024-12-04 | 6-K | 2024-12-04 | ASTRAZENECA APPOINTS ISKRA REIC EVP INTERNATIONAL | a8097o.htm |
| 2024-12-02 | 6-K | 2024-12-02 | BLOCK LISTING INTERIM REVIEW | a3952o.htm |
| 2024-12-02 | 6-K | 2024-12-02 | TOTAL VOTING RIGHTS | a3917o.htm |
| 2024-11-25 | 6-K | 2024-11-25 | TRUQAP IMPROVED RPFS IN ADVANCED PROSTATE CANCER | a4123n.htm |
| 2024-11-20 | 6-K | 2024-11-20 | DIRECTOR/PDMR SHAREHOLDING | a0144n.htm |
| 2024-11-18 | 6-K | 2024-11-18 | TAGRISSO RECOMMENDED FOR EU APPROVAL - LAURA | a5115m.htm |
| 2024-11-15 | 6-K | 2024-11-15 | DIRECTOR/PDMR SHAREHOLDING | a4728m.htm |
| 2024-11-15 | 6-K | 2024-11-15 | DIRECTOR/PDMR SHAREHOLDING | a4252m.htm |
| 2024-11-13 | 6-K | 2024-11-13 | DIRECTOR/PDMR SHAREHOLDING | a1407m.htm |
| 2024-11-12 | 6-K | 2024-11-12 | ASTRAZENECA INVESTS $3.5 BILLION IN US | a8036l.htm |
| 2024-11-12 | 6-K | 2024-11-12 | KOMET PHASE III TRIAL MET PRIMARY ENDPOINT | a7970l.htm |
| 2024-11-12 | 6-K | 2024-11-12 | 9M AND Q3 2024 RESULTS | a7967l.htm |
| 2024-11-12 | 6-K | 2024-11-12 | DATO-DXD NEW BLA SUBMITTED, NSQ BLA WITHDRAWN | a7952l.htm |
| 2024-11-08 | 6-K | 2024-11-08 | TEZSPIRE NASAL POLYPS TRIAL MET PRIMARY ENDPOINTS | a5104l.htm |
| 2024-11-01 | 6-K | 2024-11-01 | TOTAL VOTING RIGHTS | a4905k.htm |
| 2024-10-30 | 6-K | 2024-10-30 | AZN CHINA PRESIDENT UNDER INVESTIGATION | a2709k.htm |
| 2024-10-21 | 6-K | 2024-10-21 | FORM 6-K | tm_6k.htm |
| 2024-10-07 | 6-K | 2024-10-07 | ASTRAZENECA LICENSES LIPID LOWERING LP(A) ASSET | a0905h.htm |
| 2024-10-01 | 6-K | 2024-10-01 | TOTAL VOTING RIGHTS | a4718g.htm |
| 2024-09-26 | 6-K | 2024-09-26 | TAGRISSO US APPROVAL IN UNRESECTABLE LUNG CANCER | a7133f.htm |
| 2024-09-23 | 6-K | 2024-09-23 | FASENRA RECOMMENDED FOR EU APPROVAL IN EGPA | a1419f.htm |
| 2024-09-23 | 6-K | 2024-09-23 | FINAL OS RESULTS REPORTED FOR TROPION - BREAST01 | a1425f.htm |
| 2024-09-20 | 6-K | 2024-09-20 | FLUMIST APPROVED FOR SELF-ADMINISTRATION IN US | astrazenecaplc-1262f.htm |
| 2024-09-18 | 6-K | 2024-09-18 | FASENRA EGPA US FDA APPROVAL | astrazenecaplc.htm |
| 2024-09-13 | 6-K | 2024-09-13 | DIRECTOR/PDMR SHAREHOLDING | a1893e.htm |
| 2024-09-03 | 6-K | 2024-09-02 | TOTAL VOTING RIGHTS | a5295c.htm |
| 2024-08-16 | 6-K | 2024-08-16 | IMFINZI APPROVED IN US FOR RESECTABLE LUNG CANCER | a6772a.htm |
| 2024-08-01 | 6-K | 2024-08-01 | TOTAL VOTING RIGHTS | a8197y.htm |
| 2024-07-30 | 6-K | 2024-07-30 | ASTRAZENECA PRICES A EUR1.4BN BOND OFFERING | a2875y.htm |
| 2024-07-29 | 6-K | 2024-07-29 | CALQUENCE FIXED-DURATION COMBO IMPROVED 1L CLL PFS | a1031y.htm |
| 2024-07-26 | 6-K | 2024-07-26 | ODAC REVIEWED IMFINZI IN RESECTABLE LUNG CANCER | astrazenecaplc.htm |
| 2024-07-25 | 6-K | 2024-06-30 | FORM 6K | azn-20240630x6k.htm |
| 2024-07-15 | 6-K | 2024-07-15 | ACQUISITION OF AMOLYT PHARMA COMPLETED | a2927w.htm |
| 2024-07-01 | 6-K | 2024-07-01 | TOTAL VOTING RIGHTS | a6100u.htm |
| 2024-07-01 | 6-K | 2024-07-01 | LYNPARZA & IMFINZI POSITIVE CHMP IN ENDOMETRIAL | astrazenecaplc-4507u.htm |
| 2024-06-25 | 6-K | 2024-06-25 | UPDATE ON IMFINZI ADJUVANT BR.31 TRIAL | a7460t.htm |
| 2024-06-25 | 6-K | 2024-06-25 | IMFINZI IMPROVED EFS AND OS IN BLADDER CANCER | a7454t.htm |
| 2024-06-18 | 6-K | 2024-06-18 | UPDATE ON CAPITELLO-290 PHASE III TRIAL | a8461s.htm |
| 2024-06-17 | 6-K | 2024-06-17 | IMFINZI APPROVED IN THE US FOR ENDOMETRIAL CANCER | astrazenecaplc-6004s.htm |
| 2024-06-12 | 6-K | 2024-06-12 | DIRECTOR/PDMR SHAREHOLDING | astrazenecaplc-1740s.htm |
| 2024-06-04 | 6-K | 2024-06-04 | FORM 6-K | tm2416399d1_6k.htm |
| 2024-06-03 | 6-K | 2024-06-03 | BLOCK LISTING INTERIM REVIEW | a6888q.htm |
| 2024-06-03 | 6-K | 2024-06-03 | TOTAL VOTING RIGHTS | a6867q.htm |
| 2024-06-03 | 6-K | 2024-06-03 | TAGRISSO PLUS CHEMO RECOMMENDED FOR APPROVAL IN EU | a7537q.htm |
| 2024-05-28 | 6-K | 2024-05-28 | DATO-DXD IMPROVED OS IN NONSQUAMOUS LUNG CANCER | a9402p.htm |
| 2024-05-21 | 6-K | 2024-05-21 | ASTRAZENECA TO DELIVER $80BN REVENUE BY 2030 | a1880p.htm |
| 2024-05-20 | 6-K | 2024-05-20 | ASTRAZENECA TO MANUFACTURE ADCS IN SINGAPORE | a0072p.htm |
| 2024-05-16 | 6-K | 2024-05-16 | SUPERNOVA TRIAL MET COVID-19 PREVENTION ENDPOINT | a6269o.htm |
| 2024-05-15 | 6-K | 2024-05-15 | DIRECTOR/PDMR SHAREHOLDING | a5642o.htm |
| 2024-05-07 | 6-K | 2024-05-07 | ASTRAZENECA COMPLETES CELLECTIS EQUITY INVESTMENT | a3879n.htm |
| 2024-05-02 | 6-K | 2024-05-02 | CALQUENCE COMBINATION IMPROVED PFS IN 1L MCL | a9173m.htm |
| 2024-05-01 | 6-K | 2024-05-01 | TOTAL VOTING RIGHTS | a8136m.htm |
| 2024-04-29 | 6-K | 2024-04-29 | TRUQAP RECOMMENDED FOR EU BREAST CANCER APPROVAL | astrazenecaplc3089m.htm |
| 2024-04-29 | 6-K | 2024-04-29 | ENHERTU IMPROVED PFS IN HER2-LOW AND ULTRALOW | a3085m.htm |
| 2024-04-25 | 6-K | 2024-04-25 | 1ST QUARTER RESULTS | a9413l.htm |
| 2024-04-11 | 6-K | 2024-04-11 | RESULT OF AGM | a3425k.htm |
| 2024-04-11 | 6-K | 2024-04-11 | ASTRAZENECA INCREASES 2024 DIVIDEND BY 7% | astrazenecaplc.htm |
| 2024-04-08 | 6-K | 2024-04-08 | ENHERTU APPROVED IN US FOR HER2+ SOLID TUMOURS | astrazenecaplc-5918j.htm |
| 2024-04-05 | 6-K | 2024-04-05 | IMFINZI IMPROVED OS & PFS IN LIMITED-STAGE SCLC | a4121j.htm |
| 2024-04-02 | 6-K | 2024-04-02 | TOTAL VOTING RIGHTS | a9592i.htm |
| 2024-04-02 | 6-K | 2024-04-02 | VOYDEYA APPROVED IN US | a9026i.htm |
| 2024-04-02 | 6-K | 2024-04-02 | FDA ACCEPTS DATO-DXD BLA FOR BREAST CANCER | a9023i.htm |
| 2024-03-25 | 6-K | 2024-03-25 | ULTOMIRIS APPROVED IN THE US FOR NMOSD | a0626i.htm |
| 2024-03-19 | 6-K | 2024-03-19 | FORM 6-K | tm249109d1_6k.htm |
| 2024-03-14 | 6-K | 2024-03-14 | ASTRAZENECA TO ACQUIRE AMOLYT | a8420g.htm |
| 2024-03-12 | 6-K | 2024-03-12 | DIRECTOR/PDMR SHAREHOLDING | astrazenecaplc-5242g.htm |
| 2024-03-07 | 6-K | 2024-03-07 | NOTICE OF AGM | a0040g.htm |
| 2024-03-07 | 6-K | 2024-03-07 | FORM 6-K | tm247874d1_6k.htm |
| 2024-03-06 | 6-K | 2024-03-06 | DIRECTOR/PDMR SHAREHOLDING | a8467f.htm |
| 2024-03-06 | 6-K | 2024-03-06 | DIRECTOR/PDMR SHAREHOLDING | a8456f.htm |
| 2024-03-04 | 6-K | 2024-03-04 | EMA VALIDATES DATO-DXD MAAS FOR NSQ NSCLC AND BC | a4130f.htm |
| 2024-03-01 | 6-K | 2024-03-01 | TOTAL VOTING RIGHTS | a2656f.htm |
| 2024-02-26 | 6-K | 2024-02-26 | VOYDEYA RECOMMENDED FOR EU APPROVAL | a3190e.htm |
| 2024-02-26 | 6-K | 2024-02-26 | FORM 6-K | tm246099d6_6k.htm |
| 2024-02-22 | 6-K | 2024-02-22 | ASTRAZENECA PRICES A $5BN BOND OFFERING | a0139e.htm |
| 2024-02-22 | 6-K | 2024-02-22 | DIRECTOR/PDMR SHAREHOLDING | a9867d.htm |
| 2024-02-22 | 6-K | 2024-02-22 | FORM 6-K | tm246981d1_6k.htm |
| 2024-02-21 | 6-K | 2024-02-21 | FILING OF FORM 20-F WITH SEC | a7690d.htm |
| 2024-02-20 | 6-K | 2024-02-20 | ANNUAL FINANCIAL REPORT | astrazenecaplc-7725d.htm |
| 2024-02-20 | 6-K | 2024-02-20 | ASTRAZENECA COMPLETES ACQUISITION OF ICOSAVAX | astrazenecaplcmasterform6.htm |
| 2024-02-20 | 6-K | 2024-02-20 | TAGRISSO PLUS CHEMO APPROVED IN US FOR LUNG CANCER | a5268d.htm |
| 2024-02-20 | 6-K | 2024-02-20 | FDA ACCEPTS DATO-DXD BLA FOR NONSQUAMOUS NSCLC | a5266d.htm |
| 2024-02-20 | 6-K | 2024-02-19 | TAGRISSO IMPROVED PFS IN STAGE III LUNG CANCER | a5264d.htm |
| 2024-02-20 | 6-K | 2024-02-20 | FORM 6-K | tm2333142d3_6k.htm |
| 2024-02-20 | 6-K | 2024-02-20 | FORM 6-K | tm2332933d16_6k.htm |
| 2024-02-08 | 6-K | 2024-02-08 | FINAL RESULTS | a4081c.htm |
| 2024-02-01 | 6-K | 2024-02-01 | TOTAL VOTING RIGHTS | a7394b.htm |
| 2024-01-19 | 6-K | 2024-01-19 | FORM 6-K | tm2332933d12_6k.htm |
| 2024-01-02 | 6-K | 2024-01-02 | TOTAL VOTING RIGHTS | a3874y.htm |